c-Kit inhibitor 3 is primarily used in research and therapeutic applications targeting cancers and other diseases driven by c-Kit receptor tyrosine kinase activity. It is particularly relevant in the treatment of gastrointestinal stromal tumors (GISTs), where c-Kit mutations are often present. The inhibitor works by blocking the signaling pathways that promote tumor growth and survival, thereby reducing cancer progression. Additionally, it is being explored for its potential in treating mast cell disorders, such as systemic mastocytosis, where abnormal c-Kit signaling plays a key role. Its application extends to preclinical studies for understanding the role of c-Kit in stem cell regulation and hematopoiesis.